

COT Procedures

In this guide

[In this guide](#)

1. [About the Committees - 2024](#)
2. [Preface - 2024](#)
3. [COT evaluations - 2024](#)
4. [COT Procedures - 2024](#)
5. [COT ways of working - 2024](#)
6. [Ongoing work - 2024](#)
7. [Other Committee Activities: Joint Expert Groups, Presentations and Workshop - 2024](#)
8. [Joint Expert Groups - 2024](#)
9. [Working Groups - 2024](#)
10. [Other Regulators Opinions \(ORO\) and Abbreviated \(ABB\) decisions - 2024](#)
11. [2024 Membership of the Committee on Toxicity of Chemicals in Food, Consumer Products and the Environment](#)
12. [Sub-groups active in 2024](#)
13. [Declaration of members' interests during the period of this report - 2024](#)
14. [Committee on Mutagenicity of Chemicals in Food, Consumer Products and the Environment Annual Report 2024](#)
15. [Completed Work - 2024](#)
16. [Ongoing work - COM 2024](#)
17. [Horizon scanning - COM 2024](#)
18. [2024 Membership of the Committee on Mutagenicity of Chemicals in Food, Consumer Products and the Environment](#)
19. [Declaration of members interests during the period of this report - COM 2024](#)
20. [Committee on the Carcinogenicity of Chemicals in Food, Consumer Products and the Environment Annual Report 2024](#)
21. [COC Evaluations - 2024](#)
22. [COC Ongoing topics - 2024](#)
23. [Guidance statements - COC 2024](#)
24. [Horizon scanning - COC 2024](#)
25. [COC input to other work](#)

26. [2024 Membership of the Committee on Carcinogenicity of Chemicals in Food, Consumer Products and the Environment](#)
27. [Declaration of members interests during the period of this report - COC 2024](#)

Benchmark dose modelling in a UK chemical risk assessment framework

1.66 In 2021, as part of a horizon scanning exercise, the Committee on Toxicity of Chemicals in Food, Consumer Products and the Environment (COT) identified the UK in future may need benchmark dose (BMD) modelling guidance. As part of its ongoing evaluation of New Approach Methodologies (NAMs) in chemical risk assessment, the Food Standards Agency (FSA) and the COT were considering the use and practice of BMD modelling within a UK food safety context.

1.67 The [discussion paper](#) set out the theory and practice of BMD modelling. The paper drew on previous evaluations by regulatory bodies and authorities. It also included a discussion of the areas of consensus and divergence between organisations and expert groups. The paper included a case study from the FSA Computational Fellow.

1.68 BMD modelling represents a useful tool in toxicology, but the No-observed-adverse-effect level (NOAEL) approach remains valid and, in many cases, is the only option (e.g. where effects are observed only at the highest dose). The requirement for deeper knowledge of the statistical and computational basis of the BMD approach may represent a barrier for further adoption in traditional toxicology. Applying the BMD approach to toxicology data is a more complex undertaking than the traditional NOAEL approach. Some areas where BMD modelling may provide advantages over the traditional NOAEL approach include potency comparison, establishing toxicological equivalency factors (TEFs) and for situations where a reference point needs to be identified in the absence of a NOAEL.

1.69 With respect to the development of new BMD software these have their own capabilities, which allow them to be tailored for specific scenarios and tasks. However, there is concern that the use of different software might lead to further divergence rather than convergence of BMD approaches. For example, the recent development of Bayesian BMD software as part of European Food Safety Authority (EFSA's) modelling suite raised concerns around how the Bayesian BMD

modelling is used in practice, specifically with the selection of priors and whether this would introduce subjectivity into the analysis. Uncertainties have been expressed in the literature with respect to the Environmental Protection Agency (EPA) Bayesian modelling software.

1.70 There is debate about the role of benchmark dose modelling in other areas, such as genotoxicity testing, and the COT is aware of the views on BMD modelling by other UK Scientific Advisory Committees notably the COC and COM. BMD modelling is already being used by some expert groups, such as the UK Expert Committee on Pesticides and it would be useful to capture their experience.

1.71 The Committee acknowledged the rapidly developing nature of the BMD guidance, the development of new approaches, such as Bayesian approaches; and the recent proliferation of new BMD software but noted that it was still uncertain if, or what, important divergences existed between these developments.

1.72 BMD modelling should be viewed as a step towards a larger goal of more realistic, toxicodynamic systems approaches to risk assessment. This may become more feasible with the further development of models based on *in silico* and *in vitro* approaches.

1.73 The Committee noted that BMD modelling should be taken into consideration when updating COT guidance.